Mechanisms of natural brassinosteroid-induced apoptosis of prostate cancer cells

Food and Chemical Toxicology

Volumn 50, Issue 11, 2012, Pages 4068-4076

  Steigerová, Jana ^a   Rárová, Lucie ^a   Oklešt'ková, Jana ^b   Křížová, Kateřina ^a   Levková, Monika ^a   Šváchová, Michaela ^a   Kolář, Zdeněk ^a   Strnad, Miroslav ^a,b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

Apoptosis; Brassinosteroids; Cell cycle; Hormone sensitive insensitive prostate cancer cells

Indexed keywords

24 EPIBRASSINOLIDE; 28 HOMOCASTASTERONE; ANDROGEN RECEPTOR; BRASSINOSTEROID; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ESTROGEN RECEPTOR; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DNA DETERMINATION; DRUG MECHANISM; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALE; MITOSIS INHIBITION; NICK END LABELING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRASSINOSTEROIDS; CELL CYCLE; CELL LINE, TUMOR; CHOLESTANONES; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; STEROIDS, HETEROCYCLIC;

EID: 84866296899     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.08.031     Document Type: Article

References (48)

1. Bajguz A., Tretyn A. The chemical characteristic and distribution of brassinosteroids in plants. Phytochemistry 2003, 62:1027-1046.
2. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. 2000, 27:39-66.
3. Chang W.Y., Prins G.S. Estrogen receptor-beta: implications for the prostate gland. Prostate 1999, 40:115-124.
4. Clouse S.D. Brassinosteroid signaling: novel downstream components emerge. Curr. Biol. 2002, 12:485-487.
5. Culig Z., Stober J., Gast A., Peterziel H., Hobisch A., Radmayr C., Hittmair A., Bartsch G., Cato A.C., Klocker H. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect. Prev. 1996, 20:68-75.
6. de Jong F.H., Oishi K., Hayes R.B., Bogdanowicz J.F., Raatgever J.W., van der Maas P.J., Yoshida O., Schroeder F.H. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res. 1991, 51:3445-3450.
7. Dixon R.A., Ferreira D. Genistein. Phytochemistry 2002, 60:205-211.
8. Dutertre M., Smith C.L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J. Pharmacol. Exp. Ther. 2000, 295:431-437.
9. Ellem S.J., Risbridger G.P. The dual, opposing roles of estrogen in the prostate. Ann. N.Y. Acad. Sci. 2009, 1155:174-186.
10. Fixemer T., Remberger K., Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003, 54:79-87.
11. Graña X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995, 11:211-219.
12. Gray A., Feldman H.A., McKinlay J.B., Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 1991, 73:1016-1025.
13. Griffiths K. Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate 2000, 45:87-100.
14. Ho S.M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem. 2004, 91:491-503.
15. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 1995, 55:3068-3072.
16. Ikekawa N., Zhao Y.J. Apllication of 24-epibrassinolide in agriculture. Brassinosteroids: Chemistry, Bioactivity, and Applications 1991, ACS Symp. Ser. 474. Amer. Chem. Soc, Washington, DC, pp. 280-291. H.G. Cutler, T. Yokota, G. Adam (Eds.).
17. Jarrard D.F., Kinoshita H., Shi Y., Sandefur C., Hoff D., Meisner L.F., Chang C., Herman J.G., Isaacs W.B., Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 1998, 58:5310-5314.
18. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., Thun M.J. American Cancer Society. Cancer statistics 2004. CA Cancer J. Clin. 2004, 54:8-29.
19. Kasibhatla S., Tseng B. Why target apoptosis in cancer treatment. Mol. Cancer Ther. 2003, 2:573-580.
20. Khripach V.A., Zhabinski V., de Groot A.E. Brassinosteroids, a New Class of Plant Hormones 1999, Academic Press, San Diego, p. 456.
21. Kim I.Y., Kim B.C., Seong D.H., Lee D.K., Seo J.M., Hong Y.J., Kim H.T., Morton R.A., Kim S.J. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 2002, 62:5365-5369.
22. Kim I.Y., Seong D.H., Kim B.C., Lee D.K., Remaley A.T., Leach F., Morton R.A., Kim S.J. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res. 2002, 62:3649-3653.
23. Klocker H., Culig Z., Hobisch A., Cato A.C., Bartsch G. Androgen receptor alterations in prostatic carcinoma. Prostate 1994, 25:266-273.
24. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93:5925-5930.
25. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
26. Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E.R., Reddy G.P. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002, 62:2488-2492.
27. Lau K.M., LaSpina M., Long J., Ho S.M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000, 60:3175-3182.
28. Malíková J., Swaczynová J., Kolář Z., Strnad M. Anticancer and antiproliferative activity of natural brassinosteroids. Phytochemistry 2008, 69:418-426.
29. Martel C.L., Gumerlock P.H., Meyers F.J., Lara P.N. Current strategies in the management of hormone refractory prostate cancer. Cancer. Treat. Rev. 2003, 29:171-187.
30. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 2000, 33:261-274.
31. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392:49-53.
32. Nilsson S., Gustafsson J.A. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res. 2000, 2:360-366.
33. Pettersson K., Gustafsson J.A. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 2001, 63:165-192.
34. Pilat M.J., Kamradt J.M., Pienta K.J. Hormone resistance in prostate cancer. Cancer Metastasis Rev. 1998-1999, 17:373-381.
35. Poelzl G., Kasai Y., Mochizuki N., Shaul P.W., Brown M., Mendelsohn M.E. Specific association of estrogen receptor beta with the cell cycle spindle assembly checkpoint protein, MAD2. Proc. Natl. Acad. Sci. USA 2000, 97:2836-2839.
36. Rafi M.M., Rosen R.T., Vassil A., Ho C.T., Zhang H., Ghai G., Lambert G., DiPaola R.S. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000, 20:2653-2658.
37. Rárová, L., Zahler, S., Liebl, J., Kryštof, V., Sedlák, D., Bartůněk, P., Kohout, L., Strnad, M., 2012. Brassinosteroids inhibit in vitro angiogenesis in human endothelial cells. Steroids [Epub ahead of print].
38. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 1995, 7:541-546.
39. Risbridger G.P., Bianco J.J., Ellem S.J., McPherson S.J. Oestrogens and prostate cancer. Endocr. Relat. Cancer 2003, 10:187-191.
40. Rossi V., Bellastella G., De Rosa C., Abbondanza C., Visconti D., Maione L., Chieffi P., Della Ragione F., Prezioso D., De Bellis A., Bellastella A., Sinisi A.A. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β J. Cell. Physiol. 2011, 226:1334-1339.
41. Royuela M., de Miguel M.P., Bethencourt F.R., Sánchez-Chapado M., Fraile B., Arenas M.I., Paniagua R. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J. Endocrinol. 2001, 168:447-454.
42. Samelis G.F., Skarlos D., Bafaloukos D., Kosmidis P., Anagnostopoulos A., Aravantinos G., Dimopoulos M.A. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology 2003, 61:1211-1215.
43. Signoretti S., Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator?. Am. J. Pathol. 2001, 159:13-16.
44. Steiner M.S., Raghow S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J. Urol. 2003, 21:31-36.
45. Tang D.G., Porter A.T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997, 32:284-293.
46. Torlakovic E., Lilleby W., Torlakovic G., Fosså S.D., Chibbar R. Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum. Pathol. 2002, 33:646-651.
47. Tsurusaki T., Aoki D., Kanetake H., Inoue S., Muramatsu M., Hishikawa Y., Koji T. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 2003, 88:1333-1340.
48. Van den Heuvel S., Dyson N.J. Conserved functions of the pRb and E2F families. Nat. Rev. Mol. Cell Biol. 2008, 9:713-724.